Dual agonist
What a GLP-1 receptor agonist actually does: which receptors it reaches, how it slows gastric emptying, and the satiety pathway it runs through.
What is Dual agonist?
A drug hitting two receptors at once.
Tirzepatide (GLP-1/GIP) is the one on the market, and survodutide (GLP-1/glucagon) is in late-stage trials. CagriSema is different: it pairs two separate molecules, the amylin analog cagrilintide and semaglutide, rather than one drug acting on two receptors. The term helps when a seller describes a compounded product as “dual action” without saying which two receptors they mean.
GLP-1 pipeline: survodutide, maridebart, ecnoglutide →
GLP Watchdog writes these definitions from FDA labels and peer-reviewed PubMed literature.
Where Dual agonist comes up on this site
On GLP Watchdog, Dual agonist comes up in 4 research articles and 1 FDA warning letter. Browse the FDA warning letters.
Research that discusses it
Other terms under Mechanism
- GLP-1 receptor
- GIP receptor
- Gastric emptying
- Food noise
- Triple agonist
- GLP-1 tachyphylaxis
- Non-peptide GLP-1 agonist
- A1C (glycated hemoglobin)
- MASH / MASLD
- TBWL (Total Body Weight Loss)
- C-peptide
- eGFR (estimated glomerular filtration rate)
- Visceral adipose tissue (VAT)
- AHI (apnea-hypopnea index)
- SNAC (oral semaglutide absorption enhancer)
Where the evidence lives
- The full GLP-1 glossary (150 terms, 8 categories)
- Research articles — written from primary sources
- Tools and calculators
- Compare GLP-1 telehealth providers